Anti-PCSK9 antibody (590-692)

Clonality:	Polyclonal
Conjugation:	Unconjugated
Isotype:	IgG
Formulation:	PBS with 0.05% Proclin300, 50% Glycerol, pH7.3.
Purification:	Affinity purification
Dilution Range:	WB 1:500-1:1000 IF/ICC 1:50-1:200
Storage Instruction:	Store at-20°C for up to 1 year from the date of receipt, and avoid repeat freeze-thaw cycles.

Gene Symbol:	PCSK9
Gene ID:	255738
Uniprot ID:	PCSK9_HUMAN
Immunogen Region:	590-692
Immunogen:	A synthetic peptide corresponding to a sequence within amino acids 590-692 of human Proprotein Convertase 9 (PCSK9) (NP_777596.2).
Immunogen Sequence:	GHREASIHASCCHAPGLECK VKEHGIPAPQEQVTVACEEG WTLTGCSALPGTSHVLGAYA VDNTCVVRSRDVSTTGSTSE GAVTAVAICCRSRHLAQASQ ELQ

Tissue Specificity	Expressed in neuro-epithelioma, colon carcinoma, hepatic and pancreatic cell lines, and in Schwann cells.
Post Translational Modifications	Cleavage by furin and PCSK5 generates a truncated inactive protein that is unable to induce LDLR degradation. Undergoes autocatalytic cleavage in the endoplasmic reticulum to release the propeptide from the N-terminus and the cleavage of the propeptide is strictly required for its maturation and activation. The cleaved propeptide however remains associated with the catalytic domain through non-covalent interactions, preventing potential substrates from accessing its active site. As a result, it is secreted from cells as a propeptide-containing, enzymatically inactive protein. Phosphorylation protects the propeptide against proteolysis.
Function	Crucial player in the regulation of plasma cholesterol homeostasis. Binds to low-density lipid receptor family members: low density lipoprotein receptor (LDLR), very low density lipoprotein receptor (VLDLR), apolipoprotein E receptor (LRP1/APOER) and apolipoprotein receptor 2 (LRP8/APOER2), and promotes their degradation in intracellular acidic compartments. Acts via a non-proteolytic mechanism to enhance the degradation of the hepatic LDLR through a clathrin LDLRAP1/ARH-mediated pathway. May prevent the recycling of LDLR from endosomes to the cell surface or direct it to lysosomes for degradation. Can induce ubiquitination of LDLR leading to its subsequent degradation. Inhibits intracellular degradation of APOB via the autophagosome/lysosome pathway in a LDLR-independent manner. Involved in the disposal of non-acetylated intermediates of BACE1 in the early secretory pathway. Inhibits epithelial Na(+) channel (ENaC)-mediated Na(+) absorption by reducing ENaC surface expression primarily by increasing its proteasomal degradation. Regulates neuronal apoptosis via modulation of LRP8/APOER2 levels and related anti-apoptotic signaling pathways.
Protein Name	Proprotein Convertase Subtilisin/Kexin Type 9 Neural Apoptosis-Regulated Convertase 1 Narc-1 Proprotein Convertase 9 Pc9 Subtilisin/Kexin-Like Protease Pc9
Database Links	Reactome: R-HSA-381426 Reactome: R-HSA-8866427 Reactome: R-HSA-8957275 Reactome: R-HSA-8964038
Cellular Localisation	Cytoplasm Secreted Endosome Lysosome Cell Surface Endoplasmic Reticulum Golgi Apparatus Autocatalytic Cleavage Is Required To Transport It From The Endoplasmic Reticulum To The Golgi Apparatus And For The Secretion Of The Mature Protein Localizes To The Endoplasmic Reticulum In The Absence Of Ldlr And Colocalizes To The Cell Surface And To The Endosomes/Lysosomes In The Presence Of Ldlr The Sorting To The Cell Surface And Endosomes Is Required In Order To Fully Promote Ldlr Degradation
Alternative Antibody Names	Anti-Proprotein Convertase Subtilisin/Kexin Type 9 antibody Anti-Neural Apoptosis-Regulated Convertase 1 antibody Anti-Narc-1 antibody Anti-Proprotein Convertase 9 antibody Anti-Pc9 antibody Anti-Subtilisin/Kexin-Like Protease Pc9 antibody Anti-PCSK9 antibody Anti-NARC1 antibody Anti-PSEC0052 antibody

Information sourced from Uniprot.org

12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance